Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2012 (2012), Article ID 417941, 8 pages
http://dx.doi.org/10.1155/2012/417941
Clinical Study

Early Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in Yogyakarta

1Pediatric Hematology and Oncology Division, Department of Pediatrics, Dr. Sardjito Hospital, Medical Faculty, Universitas Gadjah Mada, Yogyakarta, Indonesia
2Department of Epidemiology and Biostatistics, VU University Medical Center, 1007MB Amsterdam, The Netherlands
3Pediatric Oncology/Hematology Division, Department of Pediatrics, VU University Medical Center, 1007MB Amsterdam, The Netherlands

Received 23 November 2011; Revised 24 January 2012; Accepted 25 January 2012

Academic Editor: A. J. M. Balm

Copyright © 2012 Pudjo H. Widjajanto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. H. Pui and W. E. Evans, “Treatment of acute lymphoblastic leukemia,” The New England Journal of Medicine, vol. 354, no. 2, pp. 166–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Riehm, A. Reiter, M. Schrappe et al., “Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83),” Klinische Padiatrie, vol. 199, pp. 151–160, 1987. View at Google Scholar
  3. D. R. Miller, P. F. Coccia, W. A. Bleyer et al., “Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group,” Journal of Clinical Oncology, vol. 7, no. 12, pp. 1807–1815, 1989. View at Google Scholar · View at Scopus
  4. P. S. Gaynon, W. A. Bleyer, P. G. Steinherz et al., “Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features,” Medical and Pediatric Oncology, vol. 18, no. 4, pp. 273–279, 1990. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Gajjar, R. Ribeiro, M. L. Hancock et al., “Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia,” Blood, vol. 86, no. 4, pp. 1292–1295, 1995. View at Google Scholar · View at Scopus
  6. P. G. Steinherz, P. S. Gaynon, J. C. Breneman et al., “Cytoreduction and prognosis in acute lymphoblastic leukemia—the importance of early marrow response: report from the Childrens Cancer Group,” Journal of Clinical Oncology, vol. 14, no. 2, pp. 389–398, 1996. View at Google Scholar · View at Scopus
  7. M. Schrappe, A. Reiter, H. Riehm et al., “Cytoreduction and prognosis in childhood acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 14, no. 8, pp. 2403–2406, 1996. View at Google Scholar · View at Scopus
  8. K. R. Schultz, B. Massing, J. J. Spinelli, P. S. Gaynon, and L. Wadsworth, “Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia,” Medical and Pediatric Oncology, vol. 29, no. 1, pp. 16–22, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. S. J. Laughton, L. J. Ashton, E. Kwan, M. D. Norris, M. Haber, and G. M. Marshall, “Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2264–2271, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. P. S. Gaynon, A. A. Desai, B. C. Bostrom et al., “Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review,” Cancer, vol. 80, no. 9, pp. 1717–1726, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Donadieu and C. Hill, “Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review,” British Journal of Haematology, vol. 115, no. 1, pp. 34–45, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Smith, A. Bleyer, W. Crist, S. Murphy, and S. E. Sallan, “Uniform criteria for childhood acute lymphoblastic leukemia risk classification [2],” Journal of Clinical Oncology, vol. 14, no. 2, pp. 680–681, 1996. View at Google Scholar · View at Scopus
  13. T. Flohr, A. Schrauder, G. Cazzaniga et al., “Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia,” Leukemia, vol. 22, no. 4, pp. 771–782, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Ratei, G. Basso, M. Dworzak et al., “Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction,” Leukemia, vol. 23, no. 3, pp. 528–534, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Basso, M. Veltroni, M. G. Valsecchi et al., “Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5168–5174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. V. Conter, C. R. Bartram, M. G. Valsecchi et al., “Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFMALL 2000 study,” Blood, vol. 115, no. 16, pp. 3206–3214, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Schrappe, M. G. Valsecchi, C. R. Bartram et al., “Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study,” Blood, vol. 118, no. 8, pp. 2077–2084, 2011. View at Publisher · View at Google Scholar
  18. A. J. P. Veerman, Sutaryo, and Sumadiono, “Twinning: a rewarding scenario for development of oncology services in transitional countries,” Pediatric Blood and Cancer, vol. 45, no. 2, pp. 103–106, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. J. P. Veerman, K. Hählen, W. A. Kamps et al., “High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the dutch childhood leukemia study group,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 911–918, 1996. View at Google Scholar · View at Scopus
  20. M. Schrappe, A. Reiter, S. Sauter et al., “Concept of interim analysis of trial ALL-BFM 90 for the treatment of children and adolescents with acute lymphoblastic leukemia: significance of therapy response in peripheral blood and bone marrow,” Klinische Padiatrie, vol. 206, no. 4, pp. 208–221, 1994. View at Google Scholar
  21. K. R. Schultz, D. J. Pullen, H. N. Sather et al., “Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG),” Blood, vol. 109, no. 3, pp. 926–935, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Dördelmann, A. Reiter, A. Borkhardt et al., “Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia,” Blood, vol. 94, no. 4, pp. 1209–1217, 1999. View at Google Scholar · View at Scopus
  23. M. Arico, G. Basso, F. Mandelli et al., “Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia,” Cancer, vol. 75, no. 7, pp. 1684–1693, 1995. View at Publisher · View at Google Scholar
  24. T. C. Griffin, J. J. Shuster, G. R. Buchanan, S. B. Murphy, B. M. Camitta, and M. D. Amylon, “Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study,” Leukemia, vol. 14, no. 5, pp. 792–795, 2000. View at Google Scholar · View at Scopus
  25. M. Schrappe, M. Aricò, J. Harbott et al., “Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome,” Blood, vol. 92, no. 8, pp. 2730–2741, 1998. View at Google Scholar · View at Scopus
  26. A. Roy, M. Bradburn, A. V. Moorman et al., “Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial,” British Journal of Haematology, vol. 129, no. 1, pp. 35–44, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Rautonen, L. Hovi, and M. A. Siimes, “Slow disappearance of peripheral blast cells: an independent risk factor indicating poor prognosis in children with acute lymphoblastic leukemia,” Blood, vol. 71, no. 4, pp. 989–991, 1988. View at Google Scholar · View at Scopus
  28. G. J. L. Kaspers, R. Pieters, C. H. van Zantwijk, E. R. van Wering, van der Does-van den Berg, and A. J. R. Veerman, “Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs,” Blood, vol. 92, no. 1, pp. 259–266, 1998. View at Google Scholar · View at Scopus
  29. V. Conter, M. Aricò, M. G. Valsecchi et al., “Long-term results of the Italian association of pediatric hematology and oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995,” Leukemia, vol. 14, no. 12, pp. 2196–2204, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Schrappe, A. Reiter, M. Zimmermann et al., “Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995,” Leukemia, vol. 14, no. 12, pp. 2205–2222, 2000. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Thyss, S. Suciu, Y. Bertrand et al., “Systemic effect of intrathecal methotrexate during the initial phase of treatment of childhood acute lymphoblastic leukemia,” Journal of Clinical Oncology, vol. 15, no. 5, pp. 1824–1830, 1997. View at Google Scholar
  32. F. F. Quddus, B. G. Leventhal, J. M. Boyett, D. J. Pullen, W. M. Crist, and M. J. Borowitz, “Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a pediatric oncology group study,” Cancer Research, vol. 45, no. 12, pp. 6482–6486, 1985. View at Google Scholar
  33. J. C. Barredo, T. W. Synold, J. Laver et al., “Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia,” Blood, vol. 84, no. 2, pp. 564–569, 1994. View at Google Scholar · View at Scopus
  34. W. A. Kamps, A. J. P. Veerman, E. R. van Wering, J. F. van Weerden, R. Slater, and A. van der Does-van den Berg, “Long-term follow-up of Dutch childhood leukemia study group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984–1991,” Leukemia, vol. 14, no. 12, pp. 2240–2246, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. M. N. Sitaresmi, S. Mostert, C. M. Gundy, Sutaryo, and A. J. P. Veerman, “Health-care providers' compliance with childhood acute lymphoblastic leukemia protocol in Indonesia,” Pediatric Blood and Cancer, vol. 51, no. 6, pp. 732–736, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. M. N. Sitaresmi, S. Mostert, R. M. Schook, Sutaryo, and A. J. P. Veerman, “Treatment refusal and abandonment in childhood acute lymphoblastic leukemia in Indonesia: an analysis of causes and consequences,” Psycho-Oncology, vol. 19, no. 4, pp. 361–367, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Mostert, M. N. Sitaresmi, C. M. Gundy, Sutaryo, and A. J. P. Veerman, “Influence of socioeconomic status on childhood acute lymphoblastic leukemia treatment in Indonesia,” Pediatrics, vol. 118, no. 6, pp. e1600–e1606, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Bonilla, N. Moreno, N. Marina et al., “Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador,” Journal of Pediatric Hematology/Oncology, vol. 22, no. 6, pp. 495–501, 2000. View at Google Scholar · View at Scopus
  39. M. L. Metzger, S. C. Howard, L. C. Fu et al., “Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries,” The Lancet, vol. 362, no. 9385, pp. 706–708, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Lilleyman, “Simple deliverable therapy needed for childhood leukaemia,” The Lancet, vol. 362, no. 9385, pp. 676–677, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. A. M. Slats, R. M. Egeler, A. van der Does-van den Berg et al., “Causes of death—other than progressive leukemia—in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhoold Oncology Group experience,” Leukemia, vol. 19, no. 4, pp. 537–544, 2005. View at Publisher · View at Google Scholar · View at Scopus